Pharmacoeconomic evaluation is an analytical tool used with increasing frequency to assist decision making in the financing and management of pharmaceutical products in the healthcare system or national health insurance programs of an individual country. Pharmacoeconomic (PE) guidelines can be used as a standard for preparation of studies to be included in application for reimbursement, a guide for designing and conducting a study, or a template for evaluating the economic study reports.

What does "Pharmacoeconomic Guidelines Around the World" provide?

"Pharmacoeconomic Guidelines Around the World" provides the following for each country listed:

  • The 33 key features  are: (1) type, (2) title and year of the document, (3) affiliation of authors, (4) main policy objective, (5) standard reporting format included, (6) disclosure of funding/ authors' interests, (7) target audience, (8) perspective, (9) indication, (10) target population, (11) subgroup analysis, (12) choice of comparator, (13) time horizon, (14) assumptions required, (15) preferred analytical technique, (16) costs to be included, (17) source of costs, (18) modeling, (19) systematic review of evidences, (20) preference for effectiveness over efficacy, (21) preferred outcome measure, (22) preferred method to derive utility, (23) equity issue stated, (24) discounting costs, (25) discounting outcomes, (26) sensitivity analysis- parameters and range, (27) sensitivity analysis- methods, (28) presenting results, (29) incremental analysis, (30) total C/E, (31) portability of results (generalizability), (32) financial impact analysis, (33) mandatory or recommended or voluntary
  • Each country-specific table also includes a hyperlink to the full text of the guideline (as copyright permission allows) or publication reference, as well as  a map of the country

Guidelines listed are dated based on the publication date of the document and categorized as follows:

  1. Published PE Recommendations: they are country-specific economic evaluation guidelines or recommendations published by experts in the field but are not “officially” recognized or required by the healthcare decision-making bodies/entities in this country/region for reimbursement.
  2. PE Guidelines: they are country-specific “official” guidelines or policies concerning economic evaluation that are recognized or required by the healthcare decision-making bodies/entities in this country/region for reimbursement.
  3. Submission Guidelines: they are country-specific “official” guidelines or policies concerning drug submission requirements with an economic evaluation part/section and are required by the healthcare decision-making bodies/entities in this country/region for reimbursement.

As a reference for the development of this information, please see: Health Care System Information Sharing. The reference citation is: Eldessouki R, Smith MD, Health Care System Information Sharing: A Step Toward Better Health Globally. Value Health Regional Issues 2012; 1:118-129




Recently Updated Guidelines/Recommendations 

Switzerland

Mar 19, 2022, 01:43 AM
Title : Switzerland
Current date : Jan 16, 2024, 09:42 AM

Operationalization of the Terms Effectiveness, Appropriateness and Economic Efficiency (2022).

PDF in German

The objective of this document is to operationalize the three criteria “Effectiveness, Appropriateness, Economic Efficiency”, abbreviated as EAE criteria (In German: Wirksamkeit, Zweckmässigkeit und Wirtschaftlichkeit, WZW) embedded in Article 32 of the Federal Law on Health Insurance (Bundesgesetz über die Krankenversicherung, KVG; SR 832.10). 
In order to be reimbursed by the national health insurance health technologies, including pharmaceuticals, have to fulfill the EAE criteria. This document is the conceptual basic document within a group of documents addressing operationalization of the criteria "Effectiveness, Appropriateness and Economic Efficiency". 
The paper starts with defining the EAE criteria within the context of reimbursement questions. The paper includes a generic step-wise operationalization approach of the EAE criteria regarding health technology assessment and health technology appraisal. Health technology-specific aspects of the EAE criteria may need further operationalization. Further documents will describe the different conditions for specific technologies. 
This document intends to support technology applicants, interest groups, advising federal commissions, policy makers and insurers when applying the three criteria within the context of the law.

If you are interested in volunteering to update a country's PE Guidelines or submitting a new country PE Guideline, please sign up here.

Switzerland

Mar 19, 2022, 01:43 AM
Title : Switzerland
Current date : Jan 16, 2024, 09:42 AM

Operationalization of the Terms Effectiveness, Appropriateness and Economic Efficiency (2022).

PDF in German

The objective of this document is to operationalize the three criteria “Effectiveness, Appropriateness, Economic Efficiency”, abbreviated as EAE criteria (In German: Wirksamkeit, Zweckmässigkeit und Wirtschaftlichkeit, WZW) embedded in Article 32 of the Federal Law on Health Insurance (Bundesgesetz über die Krankenversicherung, KVG; SR 832.10). 
In order to be reimbursed by the national health insurance health technologies, including pharmaceuticals, have to fulfill the EAE criteria. This document is the conceptual basic document within a group of documents addressing operationalization of the criteria "Effectiveness, Appropriateness and Economic Efficiency". 
The paper starts with defining the EAE criteria within the context of reimbursement questions. The paper includes a generic step-wise operationalization approach of the EAE criteria regarding health technology assessment and health technology appraisal. Health technology-specific aspects of the EAE criteria may need further operationalization. Further documents will describe the different conditions for specific technologies. 
This document intends to support technology applicants, interest groups, advising federal commissions, policy makers and insurers when applying the three criteria within the context of the law.

ISPOR routinely checks whether the guidelines listed here are current. If you know of any recent updates or any newly created guidelines not included here, please write us here.

If you would like your country’s pharmacoeconomics guidelines published on the ISPOR website or have comments/questions concerning this section of the ISPOR website, email your request here.

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×